RYK and acute lymphoblastic leukemia: The discovery of the structural and dynamic properties of the Class 1 pseudokinase domains of WNT receptors (ROR1, ROR2, RYK, PTK7) by Sheetz et al., added to drug screening, has allowed to identify ROR1 as a target of the small-molecule ponatinib, a kinase inhibitor approved by the Food Drug Administration in chronic myeloid and acute lymphoblastic leukemia, opening up wider perspectives of clinical development (Fig. 7B) [7].